首页> 美国卫生研究院文献>Aging (Albany NY) >circUBAP2 exacerbates malignant capabilities of NSCLC by targeting KLF4 through miR-3182 modulation
【2h】

circUBAP2 exacerbates malignant capabilities of NSCLC by targeting KLF4 through miR-3182 modulation

机译:Circubap2通过靶向KLF4通过MIR-3182调制加剧了NSCLC的恶性能力

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Chemo-resistance and refractoriness remain challenges for Non-small cell lung cancer (NSCLC) patients and the underlying molecular mechanisms haven’t been fully explained. In this study, we investigated the influence of circUBAP2 on the NSCLC tumor cells. This study might provide novel therapeutic targets for NSCLC treatment. Clinical samples and NSCLC cell lines were used to investigate circUBAP2 expressions and their impact on tumor cell chemo-resistance. CCK8 and transwell assays were conducted to explore the differences of NSCLC tumor proliferation and migration capabilities affected by circUBAP2. Dual-luciferase reporter gene assay was performed to explore the detailed molecular mechanism of circUBAP2 regulation network. circUBAP2 exhibited significantly elevated average level in our clinical samples of NSCLC, compared with normal tissues. CircUBAP2 level was positively correlated with disease stage and metastatic status. circUBAP2 significantly enhanced the migration, proliferation and chemo-resistance of NSCLC cell lines. Further experiments indicated that circUBAP2 promoted malignant biological behavior of NSCLC tumor cells by targeting KLF4 through modulating miR-3182 expression. Our study demonstrated for the first time that circUBAP2 played an important role exacerbating malignant capabilities of NSCLC. circUBAP2-miR3182-KLF4 regulative network demonstrated in this study could be a novel therapeutic target for future NSCLC treatment.
机译:化学抗性和耐火性仍然是非小细胞肺癌(NSCLC)患者的挑战,尚未得到充分解释的潜在的分子机制。在这项研究中,我们研究了Circubap2对NSCLC肿瘤细胞的影响。该研究可能为NSCLC治疗提供新的治疗靶标。临床样品和NSCLC细胞系用于研究昼夜水平表达及其对肿瘤细胞化学抗性的影响。进行CCK8和Transwell测定以探讨受循环系统影响的NSCLC肿瘤增殖和迁移能力的差异。进行双荧光素酶报告基因测定以探讨循环2调节网络的详细分子机制。与正常组织相比,Circubap2在NSClc的临床样本中表现出显着升高的平均水平。 Circubap2水平与疾病阶段和转移状态呈正相关。 Circubap2显着提高了NSClc细胞系的迁移,增殖和化学抗性。进一步的实验表明,通过调节miR-3182表达靶向KLF4,循环促进NSCLC肿瘤细胞的恶性生物学行为。我们的研究首次展示了Circubap2发挥了激发NSCLC的恶性能力的重要作用。 Circubap2-mir3182-KLF4在本研究中展示的调节网络可能是未来NSCLC治疗的新型治疗目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号